nodes	percent_of_prediction	percent_of_DWPC	metapath
Toremifene—breast cancer—ovarian cancer	0.53	1	CtDrD
Toremifene—ESR1—ovarian cancer	0.196	0.702	CbGaD
Toremifene—ABCB1—ovarian cancer	0.0832	0.298	CbGaD
Toremifene—ABCB1—Topotecan—ovarian cancer	0.02	0.221	CbGbCtD
Toremifene—ABCB1—Vinorelbine—ovarian cancer	0.0141	0.156	CbGbCtD
Toremifene—CYP3A4—Topotecan—ovarian cancer	0.012	0.133	CbGbCtD
Toremifene—ABCB1—Paclitaxel—ovarian cancer	0.00989	0.11	CbGbCtD
Toremifene—CYP3A4—Vinorelbine—ovarian cancer	0.00843	0.0935	CbGbCtD
Toremifene—ABCB1—Docetaxel—ovarian cancer	0.00715	0.0792	CbGbCtD
Toremifene—CYP3A4—Paclitaxel—ovarian cancer	0.00592	0.0657	CbGbCtD
Toremifene—ABCB1—Doxorubicin—ovarian cancer	0.00533	0.0591	CbGbCtD
Toremifene—ESR1—ovarian follicle—ovarian cancer	0.00447	0.272	CbGeAlD
Toremifene—CYP3A4—Docetaxel—ovarian cancer	0.00428	0.0475	CbGbCtD
Toremifene—CYP3A4—Doxorubicin—ovarian cancer	0.00319	0.0354	CbGbCtD
Toremifene—ESR1—oviduct—ovarian cancer	0.00196	0.12	CbGeAlD
Toremifene—ESR1—myometrium—ovarian cancer	0.000628	0.0383	CbGeAlD
Toremifene—ESR1—embryo—ovarian cancer	0.000604	0.0368	CbGeAlD
Toremifene—ESR1—epithelium—ovarian cancer	0.000493	0.03	CbGeAlD
Toremifene—ESR1—uterine cervix—ovarian cancer	0.000489	0.0298	CbGeAlD
Toremifene—ESR1—decidua—ovarian cancer	0.000465	0.0284	CbGeAlD
Toremifene—ESR1—endometrium—ovarian cancer	0.000442	0.0269	CbGeAlD
Toremifene—ESR1—gonad—ovarian cancer	0.00041	0.025	CbGeAlD
Toremifene—ESR1—uterus—ovarian cancer	0.000407	0.0248	CbGeAlD
Toremifene—CYP1A1—epithelium—ovarian cancer	0.000375	0.0228	CbGeAlD
Toremifene—CYP1A1—uterine cervix—ovarian cancer	0.000371	0.0226	CbGeAlD
Toremifene—ESR1—female reproductive system—ovarian cancer	0.000366	0.0223	CbGeAlD
Toremifene—ESR1—female gonad—ovarian cancer	0.000333	0.0203	CbGeAlD
Toremifene—ESR1—vagina—ovarian cancer	0.000331	0.0202	CbGeAlD
Toremifene—Ospemifene—ESR1—ovarian cancer	0.000324	0.318	CrCbGaD
Toremifene—CYP1A1—uterus—ovarian cancer	0.00031	0.0189	CbGeAlD
Toremifene—ESR1—testis—ovarian cancer	0.000295	0.018	CbGeAlD
Toremifene—CYP1A1—female reproductive system—ovarian cancer	0.000278	0.017	CbGeAlD
Toremifene—CYP1A1—female gonad—ovarian cancer	0.000253	0.0154	CbGeAlD
Toremifene—CYP1A1—vagina—ovarian cancer	0.000252	0.0153	CbGeAlD
Toremifene—ABCB1—myometrium—ovarian cancer	0.000248	0.0151	CbGeAlD
Toremifene—ABCB1—embryo—ovarian cancer	0.000238	0.0145	CbGeAlD
Toremifene—Clomifene—ESR1—ovarian cancer	0.000229	0.224	CrCbGaD
Toremifene—ESR1—lymph node—ovarian cancer	0.000214	0.013	CbGeAlD
Toremifene—CYP3A4—female reproductive system—ovarian cancer	0.000204	0.0124	CbGeAlD
Toremifene—ABCB1—epithelium—ovarian cancer	0.000195	0.0119	CbGeAlD
Toremifene—ABCB1—uterine cervix—ovarian cancer	0.000193	0.0118	CbGeAlD
Toremifene—ABCB1—decidua—ovarian cancer	0.000184	0.0112	CbGeAlD
Toremifene—ABCB1—endometrium—ovarian cancer	0.000175	0.0106	CbGeAlD
Toremifene—CYP1A1—lymph node—ovarian cancer	0.000163	0.00992	CbGeAlD
Toremifene—ABCB1—gonad—ovarian cancer	0.000162	0.00986	CbGeAlD
Toremifene—ABCB1—uterus—ovarian cancer	0.000161	0.0098	CbGeAlD
Toremifene—Tamoxifen—CYP1B1—ovarian cancer	0.000156	0.153	CrCbGaD
Toremifene—Anorexia—Melphalan—ovarian cancer	0.000145	0.00233	CcSEcCtD
Toremifene—Ataxia—Docetaxel—ovarian cancer	0.000145	0.00232	CcSEcCtD
Toremifene—ABCB1—female reproductive system—ovarian cancer	0.000145	0.00881	CbGeAlD
Toremifene—Pulmonary embolism—Epirubicin—ovarian cancer	0.000143	0.0023	CcSEcCtD
Toremifene—Hepatocellular injury—Epirubicin—ovarian cancer	0.000143	0.0023	CcSEcCtD
Toremifene—Weight increased—Paclitaxel—ovarian cancer	0.000143	0.00229	CcSEcCtD
Toremifene—Liver function test abnormal—Docetaxel—ovarian cancer	0.000142	0.00228	CcSEcCtD
Toremifene—Breast disorder—Docetaxel—ovarian cancer	0.000139	0.00223	CcSEcCtD
Toremifene—Chest pain—Vinorelbine—ovarian cancer	0.000139	0.00222	CcSEcCtD
Toremifene—Dyspnoea—Topotecan—ovarian cancer	0.000138	0.00222	CcSEcCtD
Toremifene—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000138	0.00222	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000138	0.00221	CcSEcCtD
Toremifene—Myocardial infarction—Paclitaxel—ovarian cancer	0.000137	0.0022	CcSEcCtD
Toremifene—Neuropathy peripheral—Paclitaxel—ovarian cancer	0.000137	0.0022	CcSEcCtD
Toremifene—ABCB1—bone marrow—ovarian cancer	0.000136	0.00832	CbGeAlD
Toremifene—Dyspnoea—Melphalan—ovarian cancer	0.000136	0.00217	CcSEcCtD
Toremifene—Decreased appetite—Topotecan—ovarian cancer	0.000135	0.00217	CcSEcCtD
Toremifene—Coordination abnormal—Doxorubicin—ovarian cancer	0.000135	0.00216	CcSEcCtD
Toremifene—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000134	0.00215	CcSEcCtD
Toremifene—Fatigue—Topotecan—ovarian cancer	0.000134	0.00215	CcSEcCtD
Toremifene—Constipation—Topotecan—ovarian cancer	0.000133	0.00213	CcSEcCtD
Toremifene—Pain—Topotecan—ovarian cancer	0.000133	0.00213	CcSEcCtD
Toremifene—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000132	0.00213	CcSEcCtD
Toremifene—Hepatocellular injury—Doxorubicin—ovarian cancer	0.000132	0.00213	CcSEcCtD
Toremifene—Pulmonary embolism—Doxorubicin—ovarian cancer	0.000132	0.00213	CcSEcCtD
Toremifene—Dry eye—Epirubicin—ovarian cancer	0.000132	0.00212	CcSEcCtD
Toremifene—Decreased appetite—Melphalan—ovarian cancer	0.000132	0.00212	CcSEcCtD
Toremifene—ABCB1—female gonad—ovarian cancer	0.000132	0.00802	CbGeAlD
Toremifene—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000131	0.00211	CcSEcCtD
Toremifene—Fatigue—Melphalan—ovarian cancer	0.000131	0.0021	CcSEcCtD
Toremifene—ABCB1—vagina—ovarian cancer	0.000131	0.00797	CbGeAlD
Toremifene—Nervous system disorder—Vinorelbine—ovarian cancer	0.00013	0.00209	CcSEcCtD
Toremifene—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00013	0.00209	CcSEcCtD
Toremifene—Pain—Melphalan—ovarian cancer	0.00013	0.00209	CcSEcCtD
Toremifene—Angina pectoris—Docetaxel—ovarian cancer	0.00013	0.00208	CcSEcCtD
Toremifene—Skin disorder—Vinorelbine—ovarian cancer	0.000129	0.00207	CcSEcCtD
Toremifene—Anorexia—Vinorelbine—ovarian cancer	0.000127	0.00203	CcSEcCtD
Toremifene—Asthenia—Chlorambucil—ovarian cancer	0.000125	0.00201	CcSEcCtD
Toremifene—Abnormal vision—Epirubicin—ovarian cancer	0.000125	0.002	CcSEcCtD
Toremifene—Pruritus—Chlorambucil—ovarian cancer	0.000123	0.00198	CcSEcCtD
Toremifene—Dry eye—Doxorubicin—ovarian cancer	0.000122	0.00196	CcSEcCtD
Toremifene—Weight increased—Docetaxel—ovarian cancer	0.000121	0.00194	CcSEcCtD
Toremifene—Visual impairment—Paclitaxel—ovarian cancer	0.000121	0.00194	CcSEcCtD
Toremifene—Thrombophlebitis—Epirubicin—ovarian cancer	0.00012	0.00193	CcSEcCtD
Toremifene—Dyspnoea—Vinorelbine—ovarian cancer	0.000118	0.0019	CcSEcCtD
Toremifene—Eye disorder—Paclitaxel—ovarian cancer	0.000118	0.00189	CcSEcCtD
Toremifene—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000117	0.00188	CcSEcCtD
Toremifene—ABCB1—testis—ovarian cancer	0.000117	0.00711	CbGeAlD
Toremifene—Myocardial infarction—Docetaxel—ovarian cancer	0.000116	0.00187	CcSEcCtD
Toremifene—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000116	0.00187	CcSEcCtD
Toremifene—Jaundice—Docetaxel—ovarian cancer	0.000116	0.00186	CcSEcCtD
Toremifene—Abnormal vision—Doxorubicin—ovarian cancer	0.000116	0.00185	CcSEcCtD
Toremifene—Decreased appetite—Vinorelbine—ovarian cancer	0.000115	0.00185	CcSEcCtD
Toremifene—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000115	0.00184	CcSEcCtD
Toremifene—Fatigue—Vinorelbine—ovarian cancer	0.000115	0.00184	CcSEcCtD
Toremifene—Angiopathy—Paclitaxel—ovarian cancer	0.000114	0.00183	CcSEcCtD
Toremifene—Constipation—Vinorelbine—ovarian cancer	0.000114	0.00182	CcSEcCtD
Toremifene—Pain—Vinorelbine—ovarian cancer	0.000114	0.00182	CcSEcCtD
Toremifene—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000113	0.00182	CcSEcCtD
Toremifene—Chills—Paclitaxel—ovarian cancer	0.000113	0.00181	CcSEcCtD
Toremifene—Arrhythmia—Paclitaxel—ovarian cancer	0.000112	0.0018	CcSEcCtD
Toremifene—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000112	0.0018	CcSEcCtD
Toremifene—Asthenia—Topotecan—ovarian cancer	0.000111	0.00179	CcSEcCtD
Toremifene—Alopecia—Paclitaxel—ovarian cancer	0.000111	0.00178	CcSEcCtD
Toremifene—Hot flush—Epirubicin—ovarian cancer	0.000111	0.00178	CcSEcCtD
Toremifene—Thrombophlebitis—Doxorubicin—ovarian cancer	0.000111	0.00178	CcSEcCtD
Toremifene—Vomiting—Chlorambucil—ovarian cancer	0.000111	0.00178	CcSEcCtD
Toremifene—Mental disorder—Paclitaxel—ovarian cancer	0.00011	0.00177	CcSEcCtD
Toremifene—Menopausal symptoms—Epirubicin—ovarian cancer	0.00011	0.00177	CcSEcCtD
Toremifene—Pruritus—Topotecan—ovarian cancer	0.00011	0.00176	CcSEcCtD
Toremifene—Malnutrition—Paclitaxel—ovarian cancer	0.000109	0.00176	CcSEcCtD
Toremifene—Asthenia—Melphalan—ovarian cancer	0.000109	0.00175	CcSEcCtD
Toremifene—Pruritus—Melphalan—ovarian cancer	0.000108	0.00173	CcSEcCtD
Toremifene—Cardiac failure—Epirubicin—ovarian cancer	0.000106	0.00171	CcSEcCtD
Toremifene—Lethargy—Epirubicin—ovarian cancer	0.000106	0.0017	CcSEcCtD
Toremifene—Back pain—Paclitaxel—ovarian cancer	0.000106	0.0017	CcSEcCtD
Toremifene—Tamoxifen—ESR1—ovarian cancer	0.000106	0.104	CrCbGaD
Toremifene—Diplopia—Epirubicin—ovarian cancer	0.000104	0.00167	CcSEcCtD
Toremifene—Nausea—Chlorambucil—ovarian cancer	0.000104	0.00166	CcSEcCtD
Toremifene—Vision blurred—Paclitaxel—ovarian cancer	0.000103	0.00166	CcSEcCtD
Toremifene—Hot flush—Doxorubicin—ovarian cancer	0.000103	0.00165	CcSEcCtD
Toremifene—Visual impairment—Docetaxel—ovarian cancer	0.000103	0.00165	CcSEcCtD
Toremifene—Dizziness—Topotecan—ovarian cancer	0.000103	0.00165	CcSEcCtD
Toremifene—Tremor—Paclitaxel—ovarian cancer	0.000103	0.00165	CcSEcCtD
Toremifene—Affect lability—Epirubicin—ovarian cancer	0.000102	0.00164	CcSEcCtD
Toremifene—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000102	0.00164	CcSEcCtD
Toremifene—Eye disorder—Docetaxel—ovarian cancer	9.96e-05	0.0016	CcSEcCtD
Toremifene—Vomiting—Topotecan—ovarian cancer	9.87e-05	0.00158	CcSEcCtD
Toremifene—Cardiac failure—Doxorubicin—ovarian cancer	9.85e-05	0.00158	CcSEcCtD
Toremifene—Mood swings—Epirubicin—ovarian cancer	9.85e-05	0.00158	CcSEcCtD
Toremifene—Vertigo—Paclitaxel—ovarian cancer	9.84e-05	0.00158	CcSEcCtD
Toremifene—Lethargy—Doxorubicin—ovarian cancer	9.81e-05	0.00157	CcSEcCtD
Toremifene—Leukopenia—Paclitaxel—ovarian cancer	9.8e-05	0.00157	CcSEcCtD
Toremifene—Rash—Topotecan—ovarian cancer	9.79e-05	0.00157	CcSEcCtD
Toremifene—Dermatitis—Topotecan—ovarian cancer	9.78e-05	0.00157	CcSEcCtD
Toremifene—Ataxia—Epirubicin—ovarian cancer	9.77e-05	0.00157	CcSEcCtD
Toremifene—Headache—Topotecan—ovarian cancer	9.73e-05	0.00156	CcSEcCtD
Toremifene—Clomifene—ABCB1—ovarian cancer	9.71e-05	0.0953	CrCbGaD
Toremifene—Angiopathy—Docetaxel—ovarian cancer	9.67e-05	0.00155	CcSEcCtD
Toremifene—Vomiting—Melphalan—ovarian cancer	9.67e-05	0.00155	CcSEcCtD
Toremifene—Diplopia—Doxorubicin—ovarian cancer	9.62e-05	0.00154	CcSEcCtD
Toremifene—Mediastinal disorder—Docetaxel—ovarian cancer	9.61e-05	0.00154	CcSEcCtD
Toremifene—Liver function test abnormal—Epirubicin—ovarian cancer	9.59e-05	0.00154	CcSEcCtD
Toremifene—Rash—Melphalan—ovarian cancer	9.59e-05	0.00154	CcSEcCtD
Toremifene—Dermatitis—Melphalan—ovarian cancer	9.58e-05	0.00154	CcSEcCtD
Toremifene—Chills—Docetaxel—ovarian cancer	9.56e-05	0.00153	CcSEcCtD
Toremifene—Asthenia—Vinorelbine—ovarian cancer	9.53e-05	0.00153	CcSEcCtD
Toremifene—Arrhythmia—Docetaxel—ovarian cancer	9.52e-05	0.00153	CcSEcCtD
Toremifene—Affect lability—Doxorubicin—ovarian cancer	9.46e-05	0.00152	CcSEcCtD
Toremifene—Alopecia—Docetaxel—ovarian cancer	9.42e-05	0.00151	CcSEcCtD
Toremifene—Pruritus—Vinorelbine—ovarian cancer	9.4e-05	0.00151	CcSEcCtD
Toremifene—Breast disorder—Epirubicin—ovarian cancer	9.39e-05	0.00151	CcSEcCtD
Toremifene—Mental disorder—Docetaxel—ovarian cancer	9.34e-05	0.0015	CcSEcCtD
Toremifene—Chest pain—Paclitaxel—ovarian cancer	9.32e-05	0.0015	CcSEcCtD
Toremifene—Malnutrition—Docetaxel—ovarian cancer	9.28e-05	0.00149	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	9.26e-05	0.00149	CcSEcCtD
Toremifene—Nausea—Topotecan—ovarian cancer	9.22e-05	0.00148	CcSEcCtD
Toremifene—Mood swings—Doxorubicin—ovarian cancer	9.11e-05	0.00146	CcSEcCtD
Toremifene—Ataxia—Doxorubicin—ovarian cancer	9.04e-05	0.00145	CcSEcCtD
Toremifene—Nausea—Melphalan—ovarian cancer	9.03e-05	0.00145	CcSEcCtD
Toremifene—Back pain—Docetaxel—ovarian cancer	8.98e-05	0.00144	CcSEcCtD
Toremifene—Oedema—Paclitaxel—ovarian cancer	8.93e-05	0.00143	CcSEcCtD
Toremifene—Liver function test abnormal—Doxorubicin—ovarian cancer	8.88e-05	0.00142	CcSEcCtD
Toremifene—Dizziness—Vinorelbine—ovarian cancer	8.78e-05	0.00141	CcSEcCtD
Toremifene—Nervous system disorder—Paclitaxel—ovarian cancer	8.76e-05	0.00141	CcSEcCtD
Toremifene—Angina pectoris—Epirubicin—ovarian cancer	8.75e-05	0.0014	CcSEcCtD
Toremifene—Thrombocytopenia—Paclitaxel—ovarian cancer	8.75e-05	0.0014	CcSEcCtD
Toremifene—Breast disorder—Doxorubicin—ovarian cancer	8.69e-05	0.00139	CcSEcCtD
Toremifene—Skin disorder—Paclitaxel—ovarian cancer	8.68e-05	0.00139	CcSEcCtD
Toremifene—Hyperhidrosis—Paclitaxel—ovarian cancer	8.64e-05	0.00139	CcSEcCtD
Toremifene—Anorexia—Paclitaxel—ovarian cancer	8.52e-05	0.00137	CcSEcCtD
Toremifene—ABCB1—lymph node—ovarian cancer	8.46e-05	0.00515	CbGeAlD
Toremifene—Vomiting—Vinorelbine—ovarian cancer	8.45e-05	0.00136	CcSEcCtD
Toremifene—Rash—Vinorelbine—ovarian cancer	8.38e-05	0.00134	CcSEcCtD
Toremifene—Dermatitis—Vinorelbine—ovarian cancer	8.37e-05	0.00134	CcSEcCtD
Toremifene—Headache—Vinorelbine—ovarian cancer	8.32e-05	0.00134	CcSEcCtD
Toremifene—Leukopenia—Docetaxel—ovarian cancer	8.31e-05	0.00133	CcSEcCtD
Toremifene—Weight increased—Epirubicin—ovarian cancer	8.17e-05	0.00131	CcSEcCtD
Toremifene—Angina pectoris—Doxorubicin—ovarian cancer	8.1e-05	0.0013	CcSEcCtD
Toremifene—Insomnia—Paclitaxel—ovarian cancer	8.08e-05	0.0013	CcSEcCtD
Toremifene—Dyspnoea—Paclitaxel—ovarian cancer	7.97e-05	0.00128	CcSEcCtD
Toremifene—Chest pain—Docetaxel—ovarian cancer	7.9e-05	0.00127	CcSEcCtD
Toremifene—Nausea—Vinorelbine—ovarian cancer	7.89e-05	0.00127	CcSEcCtD
Toremifene—Neuropathy peripheral—Epirubicin—ovarian cancer	7.85e-05	0.00126	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	7.85e-05	0.00126	CcSEcCtD
Toremifene—Jaundice—Epirubicin—ovarian cancer	7.81e-05	0.00125	CcSEcCtD
Toremifene—Decreased appetite—Paclitaxel—ovarian cancer	7.77e-05	0.00125	CcSEcCtD
Toremifene—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.71e-05	0.00124	CcSEcCtD
Toremifene—Fatigue—Paclitaxel—ovarian cancer	7.7e-05	0.00124	CcSEcCtD
Toremifene—Sweating—Epirubicin—ovarian cancer	7.68e-05	0.00123	CcSEcCtD
Toremifene—Pain—Paclitaxel—ovarian cancer	7.64e-05	0.00123	CcSEcCtD
Toremifene—Constipation—Paclitaxel—ovarian cancer	7.64e-05	0.00123	CcSEcCtD
Toremifene—Hepatobiliary disease—Epirubicin—ovarian cancer	7.57e-05	0.00122	CcSEcCtD
Toremifene—Oedema—Docetaxel—ovarian cancer	7.57e-05	0.00122	CcSEcCtD
Toremifene—Weight increased—Doxorubicin—ovarian cancer	7.56e-05	0.00121	CcSEcCtD
Toremifene—Nervous system disorder—Docetaxel—ovarian cancer	7.43e-05	0.00119	CcSEcCtD
Toremifene—Thrombocytopenia—Docetaxel—ovarian cancer	7.41e-05	0.00119	CcSEcCtD
Toremifene—Skin disorder—Docetaxel—ovarian cancer	7.36e-05	0.00118	CcSEcCtD
Toremifene—Neuropathy peripheral—Doxorubicin—ovarian cancer	7.26e-05	0.00117	CcSEcCtD
Toremifene—Jaundice—Doxorubicin—ovarian cancer	7.22e-05	0.00116	CcSEcCtD
Toremifene—Anorexia—Docetaxel—ovarian cancer	7.22e-05	0.00116	CcSEcCtD
Toremifene—Sweating—Doxorubicin—ovarian cancer	7.1e-05	0.00114	CcSEcCtD
Toremifene—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.01e-05	0.00112	CcSEcCtD
Toremifene—Visual impairment—Epirubicin—ovarian cancer	6.93e-05	0.00111	CcSEcCtD
Toremifene—Insomnia—Docetaxel—ovarian cancer	6.85e-05	0.0011	CcSEcCtD
Toremifene—Dyspnoea—Docetaxel—ovarian cancer	6.75e-05	0.00108	CcSEcCtD
Toremifene—Eye disorder—Epirubicin—ovarian cancer	6.72e-05	0.00108	CcSEcCtD
Toremifene—Decreased appetite—Docetaxel—ovarian cancer	6.58e-05	0.00106	CcSEcCtD
Toremifene—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.54e-05	0.00105	CcSEcCtD
Toremifene—Fatigue—Docetaxel—ovarian cancer	6.53e-05	0.00105	CcSEcCtD
Toremifene—Angiopathy—Epirubicin—ovarian cancer	6.52e-05	0.00105	CcSEcCtD
Toremifene—Mediastinal disorder—Epirubicin—ovarian cancer	6.48e-05	0.00104	CcSEcCtD
Toremifene—Pain—Docetaxel—ovarian cancer	6.48e-05	0.00104	CcSEcCtD
Toremifene—Constipation—Docetaxel—ovarian cancer	6.48e-05	0.00104	CcSEcCtD
Toremifene—Chills—Epirubicin—ovarian cancer	6.45e-05	0.00104	CcSEcCtD
Toremifene—Arrhythmia—Epirubicin—ovarian cancer	6.42e-05	0.00103	CcSEcCtD
Toremifene—Visual impairment—Doxorubicin—ovarian cancer	6.41e-05	0.00103	CcSEcCtD
Toremifene—Asthenia—Paclitaxel—ovarian cancer	6.41e-05	0.00103	CcSEcCtD
Toremifene—Alopecia—Epirubicin—ovarian cancer	6.35e-05	0.00102	CcSEcCtD
Toremifene—Pruritus—Paclitaxel—ovarian cancer	6.32e-05	0.00101	CcSEcCtD
Toremifene—Mental disorder—Epirubicin—ovarian cancer	6.3e-05	0.00101	CcSEcCtD
Toremifene—Malnutrition—Epirubicin—ovarian cancer	6.26e-05	0.001	CcSEcCtD
Toremifene—Loperamide—ABCB1—ovarian cancer	6.25e-05	0.0613	CrCbGaD
Toremifene—Eye disorder—Doxorubicin—ovarian cancer	6.22e-05	0.000997	CcSEcCtD
Toremifene—Back pain—Epirubicin—ovarian cancer	6.05e-05	0.000971	CcSEcCtD
Toremifene—Angiopathy—Doxorubicin—ovarian cancer	6.04e-05	0.000968	CcSEcCtD
Toremifene—Mediastinal disorder—Doxorubicin—ovarian cancer	6e-05	0.000962	CcSEcCtD
Toremifene—Chills—Doxorubicin—ovarian cancer	5.97e-05	0.000958	CcSEcCtD
Toremifene—Arrhythmia—Doxorubicin—ovarian cancer	5.94e-05	0.000954	CcSEcCtD
Toremifene—Dizziness—Paclitaxel—ovarian cancer	5.91e-05	0.000948	CcSEcCtD
Toremifene—Vision blurred—Epirubicin—ovarian cancer	5.9e-05	0.000946	CcSEcCtD
Toremifene—Alopecia—Doxorubicin—ovarian cancer	5.88e-05	0.000943	CcSEcCtD
Toremifene—Mental disorder—Doxorubicin—ovarian cancer	5.83e-05	0.000935	CcSEcCtD
Toremifene—Malnutrition—Doxorubicin—ovarian cancer	5.79e-05	0.000929	CcSEcCtD
Toremifene—Vomiting—Paclitaxel—ovarian cancer	5.68e-05	0.000911	CcSEcCtD
Toremifene—Rash—Paclitaxel—ovarian cancer	5.63e-05	0.000904	CcSEcCtD
Toremifene—Dermatitis—Paclitaxel—ovarian cancer	5.63e-05	0.000903	CcSEcCtD
Toremifene—Vertigo—Epirubicin—ovarian cancer	5.62e-05	0.000902	CcSEcCtD
Toremifene—Leukopenia—Epirubicin—ovarian cancer	5.6e-05	0.000899	CcSEcCtD
Toremifene—Back pain—Doxorubicin—ovarian cancer	5.6e-05	0.000899	CcSEcCtD
Toremifene—Headache—Paclitaxel—ovarian cancer	5.6e-05	0.000898	CcSEcCtD
Toremifene—Vision blurred—Doxorubicin—ovarian cancer	5.46e-05	0.000876	CcSEcCtD
Toremifene—Asthenia—Docetaxel—ovarian cancer	5.43e-05	0.000872	CcSEcCtD
Toremifene—Pruritus—Docetaxel—ovarian cancer	5.36e-05	0.00086	CcSEcCtD
Toremifene—Chest pain—Epirubicin—ovarian cancer	5.33e-05	0.000855	CcSEcCtD
Toremifene—Nausea—Paclitaxel—ovarian cancer	5.31e-05	0.000851	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.29e-05	0.000849	CcSEcCtD
Toremifene—Vertigo—Doxorubicin—ovarian cancer	5.2e-05	0.000835	CcSEcCtD
Toremifene—Leukopenia—Doxorubicin—ovarian cancer	5.18e-05	0.000832	CcSEcCtD
Toremifene—Oedema—Epirubicin—ovarian cancer	5.11e-05	0.00082	CcSEcCtD
Toremifene—Nervous system disorder—Epirubicin—ovarian cancer	5.01e-05	0.000804	CcSEcCtD
Toremifene—Dizziness—Docetaxel—ovarian cancer	5.01e-05	0.000803	CcSEcCtD
Toremifene—Thrombocytopenia—Epirubicin—ovarian cancer	5e-05	0.000802	CcSEcCtD
Toremifene—Skin disorder—Epirubicin—ovarian cancer	4.96e-05	0.000796	CcSEcCtD
Toremifene—Hyperhidrosis—Epirubicin—ovarian cancer	4.94e-05	0.000792	CcSEcCtD
Toremifene—Chest pain—Doxorubicin—ovarian cancer	4.93e-05	0.000791	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.9e-05	0.000786	CcSEcCtD
Toremifene—Anorexia—Epirubicin—ovarian cancer	4.87e-05	0.000781	CcSEcCtD
Toremifene—Vomiting—Docetaxel—ovarian cancer	4.81e-05	0.000773	CcSEcCtD
Toremifene—Rash—Docetaxel—ovarian cancer	4.77e-05	0.000766	CcSEcCtD
Toremifene—Dermatitis—Docetaxel—ovarian cancer	4.77e-05	0.000765	CcSEcCtD
Toremifene—Headache—Docetaxel—ovarian cancer	4.74e-05	0.000761	CcSEcCtD
Toremifene—Oedema—Doxorubicin—ovarian cancer	4.73e-05	0.000758	CcSEcCtD
Toremifene—Nervous system disorder—Doxorubicin—ovarian cancer	4.63e-05	0.000744	CcSEcCtD
Toremifene—Thrombocytopenia—Doxorubicin—ovarian cancer	4.63e-05	0.000742	CcSEcCtD
Toremifene—Insomnia—Epirubicin—ovarian cancer	4.62e-05	0.000741	CcSEcCtD
Toremifene—Skin disorder—Doxorubicin—ovarian cancer	4.59e-05	0.000737	CcSEcCtD
Toremifene—Hyperhidrosis—Doxorubicin—ovarian cancer	4.57e-05	0.000733	CcSEcCtD
Toremifene—Dyspnoea—Epirubicin—ovarian cancer	4.55e-05	0.000731	CcSEcCtD
Toremifene—Anorexia—Doxorubicin—ovarian cancer	4.51e-05	0.000723	CcSEcCtD
Toremifene—Nausea—Docetaxel—ovarian cancer	4.5e-05	0.000722	CcSEcCtD
Toremifene—Tamoxifen—ABCB1—ovarian cancer	4.49e-05	0.044	CrCbGaD
Toremifene—Decreased appetite—Epirubicin—ovarian cancer	4.44e-05	0.000712	CcSEcCtD
Toremifene—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.41e-05	0.000708	CcSEcCtD
Toremifene—Fatigue—Epirubicin—ovarian cancer	4.4e-05	0.000707	CcSEcCtD
Toremifene—Pain—Epirubicin—ovarian cancer	4.37e-05	0.000701	CcSEcCtD
Toremifene—Constipation—Epirubicin—ovarian cancer	4.37e-05	0.000701	CcSEcCtD
Toremifene—Insomnia—Doxorubicin—ovarian cancer	4.27e-05	0.000686	CcSEcCtD
Toremifene—Dyspnoea—Doxorubicin—ovarian cancer	4.21e-05	0.000676	CcSEcCtD
Toremifene—Decreased appetite—Doxorubicin—ovarian cancer	4.11e-05	0.000659	CcSEcCtD
Toremifene—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.08e-05	0.000655	CcSEcCtD
Toremifene—Fatigue—Doxorubicin—ovarian cancer	4.07e-05	0.000654	CcSEcCtD
Toremifene—Pain—Doxorubicin—ovarian cancer	4.04e-05	0.000648	CcSEcCtD
Toremifene—Constipation—Doxorubicin—ovarian cancer	4.04e-05	0.000648	CcSEcCtD
Toremifene—Asthenia—Epirubicin—ovarian cancer	3.66e-05	0.000588	CcSEcCtD
Toremifene—Pruritus—Epirubicin—ovarian cancer	3.61e-05	0.00058	CcSEcCtD
Toremifene—Asthenia—Doxorubicin—ovarian cancer	3.39e-05	0.000544	CcSEcCtD
Toremifene—Dizziness—Epirubicin—ovarian cancer	3.38e-05	0.000542	CcSEcCtD
Toremifene—Pruritus—Doxorubicin—ovarian cancer	3.34e-05	0.000537	CcSEcCtD
Toremifene—Vomiting—Epirubicin—ovarian cancer	3.25e-05	0.000521	CcSEcCtD
Toremifene—Rash—Epirubicin—ovarian cancer	3.22e-05	0.000517	CcSEcCtD
Toremifene—Dermatitis—Epirubicin—ovarian cancer	3.22e-05	0.000516	CcSEcCtD
Toremifene—Headache—Epirubicin—ovarian cancer	3.2e-05	0.000513	CcSEcCtD
Toremifene—Dizziness—Doxorubicin—ovarian cancer	3.13e-05	0.000501	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	3.06e-05	0.00149	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—TTF1—ovarian cancer	3.05e-05	0.00148	CbGpPWpGaD
Toremifene—Nausea—Epirubicin—ovarian cancer	3.03e-05	0.000487	CcSEcCtD
Toremifene—Vomiting—Doxorubicin—ovarian cancer	3.01e-05	0.000482	CcSEcCtD
Toremifene—Rash—Doxorubicin—ovarian cancer	2.98e-05	0.000478	CcSEcCtD
Toremifene—Dermatitis—Doxorubicin—ovarian cancer	2.98e-05	0.000478	CcSEcCtD
Toremifene—ESR1—Signaling Pathways—HSD17B6—ovarian cancer	2.97e-05	0.00144	CbGpPWpGaD
Toremifene—Headache—Doxorubicin—ovarian cancer	2.96e-05	0.000475	CcSEcCtD
Toremifene—ESR1—AP-1 transcription factor network—TP53—ovarian cancer	2.94e-05	0.00142	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	2.91e-05	0.00141	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—PGR—ovarian cancer	2.86e-05	0.00139	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	2.85e-05	0.00138	CbGpPWpGaD
Toremifene—Nausea—Doxorubicin—ovarian cancer	2.81e-05	0.00045	CcSEcCtD
Toremifene—ESR1—Gene Expression—NR5A1—ovarian cancer	2.77e-05	0.00134	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	2.76e-05	0.00134	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	2.76e-05	0.00134	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.72e-05	0.00132	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—ERBB2—ovarian cancer	2.71e-05	0.00132	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	2.7e-05	0.00131	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	2.69e-05	0.00131	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—IL6—ovarian cancer	2.69e-05	0.0013	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—MTOR—ovarian cancer	2.68e-05	0.0013	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PIK3CB—ovarian cancer	2.68e-05	0.0013	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—PARP1—ovarian cancer	2.66e-05	0.00129	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—HRAS—ovarian cancer	2.66e-05	0.00129	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	2.6e-05	0.00126	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	2.6e-05	0.00126	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—AKT1—ovarian cancer	2.54e-05	0.00123	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—DLC1—ovarian cancer	2.53e-05	0.00123	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	2.52e-05	0.00122	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—CDKN1B—ovarian cancer	2.51e-05	0.00122	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	2.48e-05	0.0012	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	2.44e-05	0.00118	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	2.41e-05	0.00117	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	2.39e-05	0.00116	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—AKT1—ovarian cancer	2.35e-05	0.00114	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	2.33e-05	0.00113	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PTEN—ovarian cancer	2.31e-05	0.00112	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	2.3e-05	0.00111	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	2.3e-05	0.00111	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	2.27e-05	0.0011	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.26e-05	0.0011	CbGpPWpGaD
Toremifene—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	2.25e-05	0.00109	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	2.22e-05	0.00108	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	2.21e-05	0.00107	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	2.21e-05	0.00107	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	2.2e-05	0.00107	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—CASP3—ovarian cancer	2.2e-05	0.00107	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—IL2—ovarian cancer	2.2e-05	0.00107	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	2.15e-05	0.00105	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NME2—ovarian cancer	2.15e-05	0.00104	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	2.14e-05	0.00104	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	2.11e-05	0.00102	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	2.11e-05	0.00102	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	2.1e-05	0.00102	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	2.1e-05	0.00102	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.09e-05	0.00102	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	2.07e-05	0.001	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	2.07e-05	0.001	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	2.07e-05	0.001	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—NRAS—ovarian cancer	2.06e-05	0.001	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—BCL9—ovarian cancer	2.06e-05	0.000999	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.05e-05	0.000995	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2e-05	0.000969	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	1.98e-05	0.000959	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—MAPK3—ovarian cancer	1.98e-05	0.000959	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	1.95e-05	0.000947	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—MYC—ovarian cancer	1.93e-05	0.000938	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	1.93e-05	0.000935	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	1.89e-05	0.000917	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	1.89e-05	0.000917	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—MAPK1—ovarian cancer	1.88e-05	0.000912	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—EGFR—ovarian cancer	1.88e-05	0.000912	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	1.87e-05	0.000905	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.83e-05	0.000886	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	1.79e-05	0.000866	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—KRAS—ovarian cancer	1.78e-05	0.000862	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.74e-05	0.000844	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	1.74e-05	0.000843	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	1.74e-05	0.000842	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NME2—ovarian cancer	1.72e-05	0.000834	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	1.71e-05	0.000832	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	1.67e-05	0.000809	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	1.66e-05	0.000805	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.65e-05	0.000799	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PIK3CA—ovarian cancer	1.63e-05	0.000792	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	1.63e-05	0.00079	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—DOK1—ovarian cancer	1.63e-05	0.00079	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.6e-05	0.000777	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	1.59e-05	0.00077	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—YAP1—ovarian cancer	1.58e-05	0.000766	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.57e-05	0.00076	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.57e-05	0.00076	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	1.54e-05	0.000747	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PPP1CC—ovarian cancer	1.53e-05	0.000743	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—HRAS—ovarian cancer	1.51e-05	0.000732	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.49e-05	0.000722	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.48e-05	0.000718	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—IL6—ovarian cancer	1.45e-05	0.000701	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CYTB—ovarian cancer	1.39e-05	0.000673	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—PGR—ovarian cancer	1.38e-05	0.000669	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	1.37e-05	0.000667	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NME2—ovarian cancer	1.37e-05	0.000666	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.36e-05	0.00066	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.36e-05	0.000658	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	1.34e-05	0.00065	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—AKT1—ovarian cancer	1.33e-05	0.000647	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.32e-05	0.000638	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—PARP1—ovarian cancer	1.28e-05	0.000622	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PPP1CC—ovarian cancer	1.21e-05	0.000588	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—BRIP1—ovarian cancer	1.21e-05	0.000588	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	1.2e-05	0.00058	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.16e-05	0.000565	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HDAC6—ovarian cancer	1.16e-05	0.000563	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.11e-05	0.00054	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.11e-05	0.000539	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CYTB—ovarian cancer	1.11e-05	0.000538	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	1.11e-05	0.000537	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	1.09e-05	0.000526	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.07e-05	0.000521	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NME2—ovarian cancer	1.06e-05	0.000514	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	1.06e-05	0.000512	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	1.05e-05	0.000507	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—PPP2R1A—ovarian cancer	1.04e-05	0.000504	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—YAP1—ovarian cancer	1.03e-05	0.000498	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	1.02e-05	0.000495	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—XIAP—ovarian cancer	1.01e-05	0.000488	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	9.8e-06	0.000476	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—BRIP1—ovarian cancer	9.69e-06	0.00047	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PPP1CC—ovarian cancer	9.69e-06	0.00047	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—EREG—ovarian cancer	9.57e-06	0.000464	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	9.49e-06	0.000461	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	9.21e-06	0.000447	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PGR—ovarian cancer	8.97e-06	0.000435	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CYTB—ovarian cancer	8.85e-06	0.000429	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.84e-06	0.000429	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	8.71e-06	0.000423	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	8.65e-06	0.000419	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.47e-06	0.000411	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PARP1—ovarian cancer	8.34e-06	0.000404	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	8.29e-06	0.000402	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	8.29e-06	0.000402	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—YAP1—ovarian cancer	8.13e-06	0.000395	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.05e-06	0.000391	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	7.96e-06	0.000386	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.83e-06	0.00038	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—BRIP1—ovarian cancer	7.73e-06	0.000375	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PPP1CC—ovarian cancer	7.73e-06	0.000375	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	7.19e-06	0.000349	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.08e-06	0.000343	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.96e-06	0.000338	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CYTB—ovarian cancer	6.83e-06	0.000331	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	6.76e-06	0.000328	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—FASN—ovarian cancer	6.63e-06	0.000322	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—SLC5A5—ovarian cancer	6.52e-06	0.000316	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—YAP1—ovarian cancer	6.5e-06	0.000315	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—SLC2A1—ovarian cancer	6.3e-06	0.000306	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.17e-06	0.000299	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CYP1B1—ovarian cancer	6.04e-06	0.000293	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—BRIP1—ovarian cancer	5.97e-06	0.00029	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PPP1CC—ovarian cancer	5.97e-06	0.00029	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.88e-06	0.000285	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.64e-06	0.000273	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TERT—ovarian cancer	5.37e-06	0.000261	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	5.36e-06	0.00026	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.33e-06	0.000259	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—FASN—ovarian cancer	5.3e-06	0.000257	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—SLC5A5—ovarian cancer	5.21e-06	0.000253	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—YAP1—ovarian cancer	5.19e-06	0.000252	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.13e-06	0.000249	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—SLC2A1—ovarian cancer	5.03e-06	0.000244	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—ABCB1—ovarian cancer	4.97e-06	0.000241	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CAV1—ovarian cancer	4.97e-06	0.000241	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—TYMS—ovarian cancer	4.88e-06	0.000237	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.82e-06	0.000234	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IL6ST—ovarian cancer	4.71e-06	0.000228	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	4.53e-06	0.00022	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—APC—ovarian cancer	4.53e-06	0.00022	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.51e-06	0.000219	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PPP2R1A—ovarian cancer	4.28e-06	0.000208	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—FASN—ovarian cancer	4.23e-06	0.000205	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—SLC5A5—ovarian cancer	4.16e-06	0.000202	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.02e-06	0.000195	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—YAP1—ovarian cancer	4e-06	0.000194	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	3.98e-06	0.000193	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—MAPK3—ovarian cancer	3.94e-06	0.000191	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CAV1—ovarian cancer	3.94e-06	0.000191	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.93e-06	0.000191	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—TYMS—ovarian cancer	3.9e-06	0.000189	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.85e-06	0.000187	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—MYC—ovarian cancer	3.83e-06	0.000186	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.76e-06	0.000182	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PIK3CG—ovarian cancer	3.59e-06	0.000174	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—ERBB2—ovarian cancer	3.51e-06	0.00017	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	3.47e-06	0.000168	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MTOR—ovarian cancer	3.47e-06	0.000168	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	3.42e-06	0.000166	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.4e-06	0.000165	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CXCL8—ovarian cancer	3.33e-06	0.000162	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—FASN—ovarian cancer	3.26e-06	0.000158	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	3.25e-06	0.000158	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.21e-06	0.000156	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CASP3—ovarian cancer	3.19e-06	0.000155	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IL2—ovarian cancer	3.18e-06	0.000154	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.17e-06	0.000154	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PIK3CD—ovarian cancer	3.15e-06	0.000153	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CAV1—ovarian cancer	3.14e-06	0.000153	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—TYMS—ovarian cancer	3.11e-06	0.000151	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CCND1—ovarian cancer	3.1e-06	0.000151	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.1e-06	0.00015	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	3.07e-06	0.000149	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MMP9—ovarian cancer	3.01e-06	0.000146	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PTEN—ovarian cancer	3e-06	0.000145	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.97e-06	0.000144	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.86e-06	0.000139	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PIK3CB—ovarian cancer	2.75e-06	0.000133	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—VEGFA—ovarian cancer	2.71e-06	0.000131	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—STAT3—ovarian cancer	2.68e-06	0.00013	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—NRAS—ovarian cancer	2.67e-06	0.00013	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—AKT1—ovarian cancer	2.66e-06	0.000129	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.64e-06	0.000128	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MAPK3—ovarian cancer	2.56e-06	0.000124	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.52e-06	0.000122	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CAV1—ovarian cancer	2.51e-06	0.000122	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MYC—ovarian cancer	2.49e-06	0.000121	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.45e-06	0.000119	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MAPK1—ovarian cancer	2.44e-06	0.000118	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—EGFR—ovarian cancer	2.44e-06	0.000118	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—TYMS—ovarian cancer	2.4e-06	0.000117	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.4e-06	0.000116	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PTEN—ovarian cancer	2.37e-06	0.000115	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—KRAS—ovarian cancer	2.3e-06	0.000112	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.29e-06	0.000111	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.19e-06	0.000106	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	2.11e-06	0.000103	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TP53—ovarian cancer	2.05e-06	9.92e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.01e-06	9.75e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HRAS—ovarian cancer	1.96e-06	9.49e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CAV1—ovarian cancer	1.94e-06	9.4e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PTEN—ovarian cancer	1.9e-06	9.2e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IL6—ovarian cancer	1.87e-06	9.08e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.76e-06	8.56e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.75e-06	8.5e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—AKT1—ovarian cancer	1.73e-06	8.38e-05	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PIK3CA—ovarian cancer	1.67e-06	8.12e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.55e-06	7.52e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PTEN—ovarian cancer	1.51e-06	7.34e-05	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—AKT1—ovarian cancer	1.37e-06	6.64e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.35e-06	6.56e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.34e-06	6.49e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PTEN—ovarian cancer	1.17e-06	5.67e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—AKT1—ovarian cancer	1.09e-06	5.3e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.07e-06	5.18e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—AKT1—ovarian cancer	8.72e-07	4.23e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PIK3CA—ovarian cancer	8.24e-07	4e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—AKT1—ovarian cancer	6.73e-07	3.27e-05	CbGpPWpGaD
